menu
    • menu

    Find Dofetilide manufacturers, exporters & distributors on PharmaCompass

    Farmak Dofetilide

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    18

    API Suppliers

    API Suppliers

    13

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    2

    EU WC

    EU WC

    0

    KDMF

    KDMF

    10

    NDC API

    NDC API

    0

    VMF

    NDC API

    8

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 386,113

    MARKET PLACE

    1

    API

    0

    FDF

    5INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    52

    FDF Dossiers

    FDF Dossiers

    42

    FDA Orange Book

    FDA (Orange Book)

    3

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    7

    Listed Dossiers

    Listed Dossiers

    1DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    2

    USP

    0

    JP

    2

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    16

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    82,188,795

    Annual Reports

    294

    Finished Drug Prices

    Listed Dossiers

    95 RELATED EXCIPIENT COMPANIES

    163EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 115256-11-6, Tikosyn, Dofetilida, Dofetilidum, Dofetilidum [inn-latin], Dofetilida [inn-spanish]
    Molecular Formula
    C19H27N3O5S2
    Molecular Weight
    441.6  g/mol
    InChI Key
    IXTMWRCNAAVVAI-UHFFFAOYSA-N
    FDA UNII
    R4Z9X1N2ND
    Dofetilide
    Dofetilide is a sulfonamide class III antiarrhythmic agent and potassium channel blocker. Dofetilide selectively blocks cardiac ion channels of the rapid component of the delayed rectifier potassium current Ikr. This antiarrhythmic agent prolongs cardiac action potential duration and effective refractory period due to delayed repolarization without affecting conduction velocity. This results in a normal sinus rhythm. Dofetilide is used in the treatment of atrial fibrillation and flutter.
    Dofetilide is an Antiarrhythmic.
    1 2D Structure

    Dofetilide

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
    2.1.2 InChI
    InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
    2.1.3 InChI Key
    IXTMWRCNAAVVAI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
    2.2 Other Identifiers
    2.2.1 UNII
    R4Z9X1N2ND
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(4-methanesulfonamidophenoxy)-2-(n-(4-methanesulfonamidophenethyl)-n-methylamine)ethane

    2. 1-mspmpe

    3. Tikosyn

    4. Uk 68798

    5. Uk-68,798

    2.3.2 Depositor-Supplied Synonyms

    1. 115256-11-6

    2. Tikosyn

    3. Dofetilida

    4. Dofetilidum

    5. Dofetilidum [inn-latin]

    6. Dofetilida [inn-spanish]

    7. Uk 68798

    8. Uk-68798

    9. Uk-68,798

    10. Dofetilide (tikosyn)

    11. N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide

    12. Beta-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide

    13. Chembl473

    14. R4z9x1n2nd

    15. N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide

    16. Chebi:4681

    17. 1-(4-methanesulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane

    18. N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide

    19. Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-

    20. Ncgc00164549-01

    21. Uk 68789

    22. Dsstox_cid_26433

    23. Dsstox_rid_81610

    24. Dsstox_gsid_46433

    25. Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-

    26. Xelide

    27. N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide

    28. Smr000466333

    29. Tikosyn (tn)

    30. Cas-115256-11-6

    31. Uk 68,798

    32. Unii-r4z9x1n2nd

    33. Hsdb 7927

    34. 1-(4-methanesulphonamidophenoxy)-2-(n-(4-methanesulphonamidophenethyl)-n-methylamino)ethane

    35. Dofetilide [usan:usp:inn:ban]

    36. Dofetilide- Bio-x

    37. Uk68798

    38. Dofetilide [mi]

    39. Dofetilide [inn]

    40. Dofetilide [jan]

    41. Dofetilide [usan]

    42. Dofetilide [vandf]

    43. Dofetilide [mart.]

    44. Dofetilide [usp-rs]

    45. Dofetilide [who-dd]

    46. Schembl16135

    47. Dofetilide (jan/usp/inn)

    48. Mls000759442

    49. Mls001424185

    50. Mls006010154

    51. Dofetilide [ema Epar]

    52. Gtpl2604

    53. Dofetilide [orange Book]

    54. Dofetilide, >=98% (hplc)

    55. Dtxsid5046433

    56. Dofetilide [usp Monograph]

    57. Hms2051n14

    58. Hms2089f03

    59. Hms2232h19

    60. Hms3261g03

    61. Hms3370b18

    62. Hms3393n14

    63. Hms3655a17

    64. Hms3715h20

    65. Zinc596731

    66. Act04222

    67. Bcp04770

    68. Hy-b0232

    69. Tox21_112178

    70. Tox21_500351

    71. Ac-385

    72. Bdbm50031720

    73. Nsc786034

    74. S1658

    75. Akos005259921

    76. Tox21_112178_1

    77. Bcp9000619

    78. Ccg-101037

    79. Db00204

    80. Nc00287

    81. Nsc-786034

    82. Uk68789

    83. Mrf-0000317

    84. N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide

    85. Ncgc00164549-02

    86. Ncgc00261036-01

    87. Bd164377

    88. Bcp0726000009

    89. Db-041252

    90. Ft-0631076

    91. Sw197667-2

    92. C07751

    93. D00647

    94. H11953

    95. Ab00639976-06

    96. Ab00639976-08

    97. Ab00639976_09

    98. 256d116

    99. A803396

    100. Sr-01000759368

    101. J-003271

    102. Q3712521

    103. Sr-01000759368-4

    104. Brd-k86887724-001-05-6

    105. Dofetilide, United States Pharmacopeia (usp) Reference Standard

    106. .beta.-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide

    107. 1-(4-methansulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane

    108. N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide

    109. (dofetilide) N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide

    110. N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide

    111. N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide

    112. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide)

    113. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (uk-68798)

    114. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide Dofetilide

    115. N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-n-methylethylamino}ethyl)phenyl]-methanesulphonamide

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 441.6 g/mol
    Molecular Formula C19H27N3O5S2
    XLogP31.8
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count11
    Exact Mass441.13921332 g/mol
    Monoisotopic Mass441.13921332 g/mol
    Topological Polar Surface Area122 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity672
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameTikosyn
    PubMed HealthDofetilide (By mouth)
    Drug ClassesAntiarrhythmic, Group III
    Drug LabelTIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Its empirical formula is C19H27N3O5S2 and it has a molecular weight of 441.6. The structural formula is The chemical name for d...
    Active IngredientDofetilide
    Dosage FormCapsule
    RouteOral
    Strength0.5mg; 0.25mg; 0.125mg
    Market StatusPrescription
    CompanyPfizer

    2 of 2  
    Drug NameTikosyn
    PubMed HealthDofetilide (By mouth)
    Drug ClassesAntiarrhythmic, Group III
    Drug LabelTIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Its empirical formula is C19H27N3O5S2 and it has a molecular weight of 441.6. The structural formula is The chemical name for d...
    Active IngredientDofetilide
    Dosage FormCapsule
    RouteOral
    Strength0.5mg; 0.25mg; 0.125mg
    Market StatusPrescription
    CompanyPfizer

    4.2 Therapeutic Uses

    Anti-Arrhythmia Agents, Potassium Channel Blockers

    National Library of Medicine's Medical Subject Headings online file (MeSH, 2011)

    Tikosyn is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    Tikosyn is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter (AF/AFl)) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    4.3 Drug Warning

    /BOXED WARNING/ To minimize the risk of induced arrhythmia, patients initiated or re-initiated on Tikosyn should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation ... . Tikosyn is available only to hospitals and prescribers who have received appropriate Tikosyn dosing and treatment initiation education;

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (Updated: February 2014). Available from, as of April 23, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c

    Tikosyn (dofetilide) can cause serious ventricular arrhythmias, primarily torsade de pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to dofetilide plasma concentration. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval. Treatment with dofetilide must therefore be started only in patients placed for a minimum of three days in a facility that can provide electrocardiographic monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Calculation of the creatinine clearance for all patients must precede administration of the first dose of dofetilide.

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    In patients with mild to moderate renal failure, decreases in dosage based on creatinine clearance are required to minimize the risk of torsades de pointes. The drug should not be used in patients with advanced renal failure or with inhibitors of renal cation transport.

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 923

    Torsades de pointes occurred in 1-3% of patients in clinical trials where strict exclusion criteria (e.g., hypokalemia) were applied and continuous ECG monitoring was used to detect marked QT prolongation in the hospital. The incidence of this adverse effect during more widespread use of the drug, marketed since 2000, is unknown. Other adverse effects were no more common than with placebo during premarketing clinical trials.

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 923

    For more Drug Warnings (Complete) data for Dofetilide (16 total), please visit the HSDB record page.

    4.4 Drug Indication

    For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm

    FDA Label

    Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:

    - Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5. 1).

    - Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.

    Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

    5.2 MeSH Pharmacological Classification

    Potassium Channel Blockers

    A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)

    Anti-Arrhythmia Agents

    Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    DOFETILIDE
    5.3.2 FDA UNII
    R4Z9X1N2ND
    5.3.3 Pharmacological Classes
    Antiarrhythmic [EPC]
    5.4 ATC Code

    C01BD04

    C - Cardiovascular system

    C01 - Cardiac therapy

    C01B - Antiarrhythmics, class i and iii

    C01BD - Antiarrhythmics, class iii

    C01BD04 - Dofetilide

    5.5 Absorption, Distribution and Excretion

    Absorption

    >90%

    Volume of Distribution

    3 L/kg

    Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. Renal elimination involves both glomerular filtration and active tubular secretion (via the cation transport system, a process that can be inhibited by cimetidine, trimethoprim, prochlorperazine, megestrol and ketoconazole). ...

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state. Oral bioavailability is unaffected by food or antacid. The terminal half life of Tikosyn is approximately 10 hours; steady state plasma concentrations are attained within 2-3 days, with an accumulation index of 1.5 to 2.0. Plasma concentrations are dose proportional. Plasma protein binding of dofetilide is 60-70%, is independent of plasma concentration, and is unaffected by renal impairment. Volume of distribution is 3 L/kg.

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    1. Pharmacokinetics of dofetilide were studied in man, dog, rat and mouse after single IV and oral doses of dofetilide or (14)C-dofetilide. 2. Dofetilide was absorbed completely in all species. Low metabolic clearance in man resulted in complete bioavailability following oral administration. Higher metabolic clearance in rodents, and to a lesser extent dogs, resulted in decreased bioavailability because of first-pass metabolism. 3. Following IV administration, the volume of distribution showed only moderate variation in all species (2.8-6.3 l/kg). High plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). 4. After single IV doses of (14)C-dofetilide, unchanged drug was the major component excreted in urine of all species with several metabolites also present. 5. Metabolites identified in urine from all species were formed by N-oxidation or N-dealkylation of the tertiary nitrogen atom of dofetilide. 6. After oral and IV administration of (14)C-dofetilide to man, parent compound was the only detectable component present in plasma and represented 75% of plasma radioactivity. No single metabolite accounted for greater than 5% of plasma radioactivity.

    PMID:1441594 Smith DA et al; Xenobiotica 22 (6): 709-19 (1992)

    5.6 Metabolism/Metabolites

    Hepatic

    Dofetilide, a class III antidysrhythmic agent, undergoes both renal and metabolic clearance. Characterization of the metabolism in vitro allows explanation of species differences, whereas identification of the human enzymes involved permits assessment of potential drug interaction. In liver microsomes, the rate of oxidative metabolism of dofetilide is in the order: male rat > female rat > dog > humans, which correlates with the metabolic clearance seen in vivo. In vitro products of oxidative metabolism, formed by N-dealkylation, are the same as those formed in vivo, with the N-desmethyl being the major product. This route of dofetilide metabolism is mediated by cytochrome P450 (CYP). In humans, N-demethylation has a high KM of 657 +/- 116 uM, indicating low affinity for the enzyme's active site. In a number of human liver microsomal preparations, this rate correlated (r = 0.903) with the activity of CYP3A4. There was no correlation with the activities of other isozymes. Specific isozyme inhibitors also indicated the involvement of CYP3A4, with partial inhibition being observed with ketoconazole and troleandeomycin, whereas the activator, alpha-naphthaflavone, caused increased turnover. No inhibition was observed with specific inhibitors or competing substrates for other isozymes. Dofetilide did not significantly inhibit CYP2C9, CYP2D6, or CYP3A4 at concentrations up to 100 microM in vitro. In contrast, amiodarone (IC50, 25 uM) and flecainide (49 microM) inhibited CYP2C9 and quinidine (0.26 uM), and flecainide (0.44 uM) inhibited CYP2D6. Many antidysrhythmic drugs have active, circulating metabolites, complicating the relationship of dose and clinical response. In vitro pharmacology studies allow assessment of the potential contribution to the pharmacological profile by metabolites. Potency of dofetilide and metabolites has been compared for class III (K+ channel blockade) and class I (Na+ channel blockade) antidysrhythmic activities. Three of the metabolites of dofetilide displayed class III activity but at concentrations at least 20-fold higher than dofetilide. Dofetilide N-oxide showed class I activity, but only at high concentration. Neither resting membrane potential or action potential amplitude were affected by any metabolite. This lack of biologically relevant activity is in accord with the close correlation between plasma concentrations of dofetilide and pharmacological response.

    PMID:8801060 Walker DK et al; Drug Metab Dispos 24 (4): 447-55 (1996)

    Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. ... In vitro studies with human liver microsomes show that dofetilide can be metabolized by CYP3A4, but it has a low affinity for this isoenzyme. Metabolites are formed by N-dealkylation and N-oxidation. There are no quantifiable metabolites circulating in plasma, but 5 metabolites have been identified in urine

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    5.7 Biological Half-Life

    10 hours

    Following IV administration, ... high plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). ...

    PMID:1441594 Smith DA et al; Xenobiotica 22 (6): 709-19 (1992)

    The terminal half life of Tikosyn is approximately 10 hours

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    5.8 Mechanism of Action

    The mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conduction in the accessory pathway).

    Rapidly activating delayed rectifier current (IKr) is the key target of class III antiarrhythmic drugs including dofetilide. Due to its complex gating properties, the precise channel state or states that interact with these agents remain poorly defined. We have undertaken a careful analysis of the state dependence of HERG channel block by dofetilide in Xenopus oocytes and Chinese Hamster Ovary (CHO) cells by devising a protocol in which brief sampling pulses were superimposed over a wide range of test potentials. The rate of block onset, maximal steady-state block and IC50 were similar for all test potentials over the activation range, demonstrating that the drug probably interacts with open and/or inactivated but not resting HERG channels with high affinity. Reducing the fraction of inactivated channels at 0 mV by augmenting the external potassium concentration did not alter the sensitivity to dofetilide. In contrast, the S631A and S620T HERG mutations both eliminated inward rectification and reduced dofetilide affinity by approximately 10- and approximately 100-fold respectively. We have also found a novel ultra-slow activation process which occurs in wild type HERG channels at threshold potentials. Overall, ... data imply that dofetilide block occurs equally at all voltages positive to the activation threshold, and that the drug interacts with HERG channels in both the open and inactivated states.

    PMID:11907818 Weerapura M et al; Pflugers Arch 443 (4): 520-31 (2002)

    Tikosyn (dofetilide) shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. At concentrations covering several orders of magnitude, dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

    US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

    The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr). HERG/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations. By contrast, the closely related bovine ether-a-go-go channel (BEAG) is 100-fold less sensitive to dofetilide. To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block. Using constructs heterologously expressed in Xenopus oocytes, we found that transplantation of the S5-S6 linker from BEAG into HERG removed high-affinity block by dofetilide. A point mutation in the S5-S6 linker region, HERG S620T, abolished high-affinity block and interfered with C-type inactivation. Thus, our results indicate that important determinants of dofetilide binding are localized to the pore region of HERG. Since the loss of high-affinity drug binding was always correlated with a loss of C-type inactivation, it is possible that the changes observed in drug binding are due to indirect allosteric modifications in the structure of the channel protein and not to the direct interaction of dofetilide with the respective mutated site chains. However, the chimeric approach was not able to identify domains outside the S5-S6 linker region of the HERG channel as putative candidates involved in drug binding. Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG K+ channels for dofetilide, whereas C-type inactivation could not be recovered. Thus, the serine in position HERG 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.

    PMID:9486667 Ficker E et al; Circ Res 82 (3): 386-9 (1998)

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642530600,"product":"DOFETILIDE ( QTY: 1 X 200 MG, PRICE: USD 752 ) (FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"USP","supplierCountry":"UNITED STATES","foreign_port":"WASHINGTON DULLES I","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"3760000","totalValueFC":"781","currency":"USD","unitRateINR":"290884400","date":"19-Jan-2022","totalValueINR":"58176.88","totalValueInUsd":"781","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7133752","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"WASHINGTON DULLES I","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"DOFETILIDE (QTY:1X0.1 GMS,PRICE: USD 23.73)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED STATES PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0001","unit":"KGS","unitRateFc":"237300","totalValueFC":"24.5","currency":"USD","unitRateINR":"18360800","date":"10-Feb-2022","totalValueINR":"1836.08","totalValueInUsd":"24.5","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7430712","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"DOFETILIDE(QTY:1X0.4 GMS,PRICE: USD 67.76)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED STATES PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0004","unit":"KGS","unitRateFc":"169400","totalValueFC":"69.9","currency":"USD","unitRateINR":"13107075","date":"10-Feb-2022","totalValueINR":"5242.83","totalValueInUsd":"69.9","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7430712","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1651689000,"product":"DOFETILIDE STANDARD - 1000 MG","address":"PLOT NOS. B5 (pt) & B6 (pt) SIPCOT","city":"SRIPERUMBUDUR","supplier":"CHEMO","supplierCountry":"ITALY","foreign_port":"NA","customer":"ORBION PHARMACEUTICALS PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"5400000","totalValueFC":"5390.5","currency":"USD","unitRateINR":"416610000","date":"05-May-2022","totalValueINR":"416610","totalValueInUsd":"5390.5","indian_port":"MADRAS AIR","hs_no":"29359090","bill_no":"8560306","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NOS. B5 (pt) & B6 (pt) SIPCOT"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675967400,"product":"DOFETILIDE USP","address":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura","city":"BANGALORE","supplier":"HYLORIS DEVELOPMENTS SA","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"MAIVA PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"30.5","unit":"GMS","unitRateFc":"200","totalValueFC":"6780.2","currency":"EUR","unitRateINR":"18360","date":"10-Feb-2023","totalValueINR":"559980","totalValueInUsd":"6780.2","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"4596882","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679077800,"product":"DOFETILIDE USP, DOFETILIDE USP MECRONIZED DRUG SUBSTANCE","address":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura","city":"BANGALORE","supplier":"HYLORIS DEVELOPMENTS SA","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"MAIVA PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.78","unit":"GMS","unitRateFc":"200","totalValueFC":"169.5","currency":"EUR","unitRateINR":"17870","date":"18-Mar-2023","totalValueINR":"13938.6","totalValueInUsd":"169.5","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"5108440","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702492200,"product":"DOFETILIDE (QTY: 1 X 200 MG, VALUE: USD 790) (FOC)","address":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,","city":"TURKAPALLY(V),SHAMEERPET, HYDERABAD","supplier":"USP","supplierCountry":"SWITZERLAND","foreign_port":"WASHINGTON, DULLES I","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"3950000","totalValueFC":"825.9","currency":"USD","unitRateINR":"343772050","date":"14-Dec-2023","totalValueINR":"68754.41","totalValueInUsd":"825.9","indian_port":"Hyderabad Air","hs_no":"29359090","bill_no":"9230967","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"WASHINGTON, DULLES I","supplierAddress":"7135 ENGLISH MUFFIN WAY FREDERICK,MD, US 21704, UNITED STATES OF AMERICA United States","customerAddress":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,"}]
    19-Jan-2022
    14-Dec-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - 0.125MG

    USFDA APPLICATION NUMBER - 20931

    read-more

    DOSAGE - CAPSULE;ORAL - 0.25MG

    USFDA APPLICATION NUMBER - 20931

    read-more

    DOSAGE - CAPSULE;ORAL - 0.5MG

    USFDA APPLICATION NUMBER - 20931

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Granulation

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search